Reuters: Global Markets: Lilly, Boehringer say diabetes drug meets goals in later trials

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Lilly, Boehringer say diabetes drug meets goals in later trials Jan 7th 2013, 13:53 Mon Jan 7, 2013 8:53am EST (Reuters) - Eli Lilly and Co and Boehringer Ingelheim said on Monday that a treatment for type 2 diabetes, empagliflozin, had been shown to work in four late-stage trials. The drug aims to reduce blood glucose levels in adults with type 2 diabetes, the most common form of diabetes in which the body either does not produce enough insulin or the cells ignore the insulin. About 371 million people worldwide are estimated to have diabetes. The companies said they expect to file for regulatory review of the drug in the United States, Europe and Japan in 2013 and will present detailed data from the trials this year and next. The companies said that among adverse reactions, genital infections occurred more often with the treatment than with the placebo. Boehringer and Lilly are collaborating on several diabetes drugs. On Monday, they said only Lilly would continue with collaboration on another one of the treatments, known as LY2605541.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions